CoChat

Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer

Open access
Matos, Ana I., Carreira, Barbara, Peres, Carina, Moura, Liane I.F., Conniot, João, Fourniols, Thibaut, Scomparin, Anna, Martínez-Barriocanal, Águeda, Arango, Diego, Conde, João P., Préat, Véronique, Satchi-Fainaro, Ronit, Florindo, Helena F. · 2019 · Journal of Controlled Release
Cited by 68

The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.

Abstract

Colorectal cancer (CRC) is among the five most commonly diagnosed cancers worldwide, constituting 6% of all cancers and the third leading cause of cancer death. CRC is the third and second most frequent cancer in men and women worldwide, accounting for 14% and 13% of all cancer incidence rates, respectively. CRC incidence is decreasing in older populations, but it has been significantly rising worldwide in adolescents and adults younger than 50 years old. Significant advances in the screening methods and surgical procedures have been underlying the reduction of the CRC incidence rate in older populations. However, there is an urgent demand for the development of alternative effective therapeutic options to overcome advanced metastatic CRC, while preventing disease recurrence. This review addresses the immune and CRC biology, summarizing the recent advances on the immune and/or therapeutic regimens currently in clinical use. We will focus on the emerging role of nanotechnology in the development of combinational therapies targeting and thereby regulating the function of the major players in CRC progression and immune evasion.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jconrel.2019.06.017

Cites

49 of 49 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 49 references

Cited by

See all 68

Metadata

Authors
Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., Préat, V., Satchi-Fainaro, R., & Florindo, H. F.
Venue
Journal of Controlled Release
Publisher
Elsevier BV
Published
2019-08
Volume
307
Pages
108-138
ISSN
0168-3659 (ISSN-L)
OpenAlex
W2951298548
Cited by
68
References
49
FWCI
2.90
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. https://app.cochat.ai/papers/10.1016/j.jconrel.2019.06.017
The paper
Matos, A. I., Carreira, B., Peres, C., Moura, L. I. F., Conniot, J., Fourniols, T., Scomparin, A., Martínez-Barriocanal, Á., Arango, D., Conde, J. P., Préat, V., Satchi-Fainaro, R., & Florindo, H. F. (2019). Nanotechnology is an important strategy for combinational innovative chemo-immunotherapies against colorectal cancer. Journal of Controlled Release. https://doi.org/10.1016/j.jconrel.2019.06.017

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.